nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.05.2024 | editorial

Congress update 2023—ASCO and ESMO

verfasst von: Univ.-Prof. Dr. Rupert Bartsch

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Excerpt

In this issue of MEMO, three articles provide in-depth views into conference news in the field of gastrointestinal cancer, breast cancer, and urogenital tumors. …

Nächster Artikel Rare lung cancer special: a multifaceted approach

Bergen ES, Ilhan-Mutlu A. Upper-GI Highlights of ASCO and ASCO-GI 2023 Meetings: Changing paradigm in treatment sequence. memo. 2024;17(2):944–8. https://doi.org/10.1007/s12254-023

Zgubic AJ, Leitsmann M, Ahyai S, Pichler MESMO. treatment changing news in urogenital cancer—a brief unstructured narrative review based on findings presented at the ESMO 2023 conference. memo. 2023;17(2):2024. https://doi.org/10.1007/s12254-024-00964-y.CrossRef

Bartsch RASCO. Highlights In Breast Cancer. memo. 2023;17(2):2024. https://doi.org/10.1007/s12254-023-00936-8.CrossRef

Titel: Congress update 2023—ASCO and ESMO
verfasst von: Univ.-Prof. Dr. Rupert Bartsch
Publikationsdatum: 01.05.2024
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-024-00968-8

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations

Open Access
short review

Brief update on systemic therapies in myeloproliferative neoplasms

Open Access
short review

Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence

Open Access
short review

ASCO 2023: highlights in breast cancer

Open Access
short review

Antibody–drug conjugates (ADC special)—part 1

editorial

The future of clinical trials—goals, ideas, and discussion

Open Access
review

Springer Medizin Österreich

Congress update 2023—ASCO and ESMO

Excerpt

Weitere Artikel der Ausgabe 2/2024

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations

Brief update on systemic therapies in myeloproliferative neoplasms

Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence

ASCO 2023: highlights in breast cancer

Antibody–drug conjugates (ADC special)—part 1

The future of clinical trials—goals, ideas, and discussion

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations

Brief update on systemic therapies in myeloproliferative neoplasms

Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence

ASCO 2023: highlights in breast cancer

Antibody–drug conjugates (ADC special)—part 1

The future of clinical trials—goals, ideas, and discussion